CLEVELAND, Sept. 10, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it is scheduled to participate at two upcoming conferences: The Stem Cells USA Regenerative Medicine Congress and the Rodman & Renshaw 2010 Annual Global Investment Conference.
Stem Cells USA Regenerative Medicine Congress
The Stem Cells USA Regenerative Medicine Congress is being held from September 13-15, 2010 at the Radisson Plaza-Warwick Hotel in Philadelphia, Pennsylvania and will bring together leaders from the pharmaceutical and biotechnology industries, as well as contract service, government and research organizations to address the opportunities and challenges for commercialization of stem cells and regenerative medicine.
Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer of Athersys will make his presentation entitled "Big Pharma and Regenerative Medicine Partnerships" on Monday, September 13, 2010 at 11:30 AM Eastern Time (ET). Dr. Van Bokkelen will address strategies for partnering with major pharmaceutical and other companies, including Athersys' partnership with Pfizer, Inc. to develop its patented and proprietary adult stem cell product MultiStem® for treatment of inflammatory bowel disease.
Dr. Van Bokkelen will also chair a panel entitled, "Autologous vs. Allogeneic Business Models" on Monday afternoon. The panel will discuss specific areas where allogeneic and autologous based therapies could be clinically and commercially relevant, and key challenges associated with the development of promising new therapies. The panel will include Dr. Devyn Smith, Senior Director, Strategic Management Group, Pfizer, Inc., Josh Hamermesh, Senior Vice President Business Development, Pervasis Therapeutics, Inc., Kenneth Aldrick, Chairman and Chief Executive Officer of International Stem Cell Corporation, and Mark Stejbach, Chief Commercial Officer, Tengion, Inc.
Rodman & Renshaw 2010 Annual Global Investment Conference
Athersys is scheduled to present at the Rodman & Renshaw 2010 Annual Global Investment Conference, being held September 12-15, 2010 at the New York Palace Hotel in New York City. William (B.J.) Lehmann, J.D., President and Chief Operating Officer, will provide a corporate and product overview of the Company on Tuesday, September 14, 2010 at 4:05 PM ET. Investors may listen to a live audio web cast of Athersys' presentation by accessing the following link: . A web cast replay of the presentation can be accessed via the Company's web site at www.athersys.com, under the "Investors / Events & Presentations" section.
About Athersys
Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem®, a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation and oncology treatment support, ischemic stroke, and inflammatory bowel disease. The Company is also developing a portfolio of other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE®). Athersys has forged several key strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at .
The Athersys, Inc. logo is available at
CONTACT: Athersys, Inc. William (B.J.) Lehmann, J.D., President and COO (216) 431-9900 bjlehmann@athersys.com In-Site Communications Investor Relations: Lisa M. Wilson (917) 543-9932 lwilson@insitecony.com Pure Communications, Inc. Media Relations: Dan Budwick (973) 271-6085 dan@purecommunicationsinc.com
